Introduction: The European Partnership for Personalised Medicine (EP PerMed), supported by the European Union under Horizon Europe, has launched its second joint transnational call (JTC2025) for proposals on "Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)".

General Description: This call aims to support multinational innovative research projects in personalised medicine (PM) by bringing together academic, clinical/public health, and private research teams. The focus is on pharmacogenomic strategies to enhance the competitiveness in Europe in this field.

Objectives:

• Identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
• Validation of pharmacogenomic markers or signatures in predicting drug or drug combination outcomes.
• Use of pharmaco-omics strategies to determine the right dosage, efficacy of treatments, and risk of adverse drug responses to tailor personalised treatment pathways.

Projects are encouraged to combine the following aspects in their research:

1. Omics data such as epigenomics, transcriptomics, proteomics and metabolomics data in addition to genomics data in relation to treatment outcomes. A key goal is to assess the importance of one or more -omics approaches (multi-modal approaches) in optimising treatment outcomes.
2. Information regarding patient medication (prescription and non-prescription), dose or compliance.
3. Information (including clinical and environmental factors) regarding medication efficacy, adverse effects and patient reported outcomes (PRO).

Projects funded under this call are furthermore required to include a dedicated work package focussing on the question of implementation of the research outcomes into clinical practice with a focus on e.g. patient outcome, costs, reimbursement, education, ELSA (ethical, legal and societal aspect) or feasible use at the point of care.

Research projects in all disease areas are welcome. Research on polygenic drug response phenotypes is encouraged.

Exclusion: Projects focussing only on drug-drug-interaction are out of scope. Projects focusing on the clinical development of new drugs are out scope.

Other Relevant Aspects:

• Encourages interdisciplinary collaborations and cross-sectorial partnerships.
• Supports participatory research with active representation of patients or citizens.
• Projects should include a dedicated work package focusing on the implementation of research outcomes into clinical practice.

Project Duration: Up to 3 years.

Call Phases:

• Pre-proposal phase.
• Full-proposal phase.

General Eligibility:

• Joint research proposals must be submitted by consortia involving at least three partners from three different EU Member States or Associated Countries.
• Consortia must include partners from academia, clinical/public health sector, and private for-profit or non-profit partners.
• Each consortium must nominate one project coordinator among the principal investigators.
• Maximum number of partners per consortium: 6 (pre-proposal stage), 7 (full-proposal stage with widening option).

Conditions:

• Applications must be submitted by startups or teams/researchers affiliated with an academic or healthcare research organization registered in an EU Member State or a Horizon Europe associated country.
• Applications must be formulated in English.
• Solutions must be at least at the proof-of-concept stage (TRL3).
• Teams should consist of up to five members with diverse backgrounds, including technical/scientific, clinical, product design/development, and business.

In case of interest, please click on "m'interessa" and we will contact you.